---
layout: default
title: Arnica Montana Root Crataegus Fruit Ether Lilium L
parent: 僅模型預測 (L5)
nav_order: 406
evidence_level: L5
indication_count: 0
---

# Arnica Montana Root Crataegus Fruit Ether Lilium L
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Botanical Complex: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This submission contains a twelve-ingredient botanical/homeopathic mixture — including Arnica Montana Root, Crataegus Fruit, Valerian, Wood Creosote, and Sanguinaria Canadensis Root, among others — with no registered market authorization in any reviewed jurisdiction.
The TxGNN model returned **no predicted indications** for this combination, likely because the multi-ingredient formulation could not be mapped to a single DrugBank entity.
Without a prediction, original indication data, or safety profile, no repurposing analysis can be meaningfully performed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (below L5 — no prediction generated) |
| Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This product is a twelve-component mixture containing both botanical extracts and non-biological excipients:

> **Arnica Montana Root · Crataegus Fruit · Ether · Lilium Lancifolium (Whole Flowering) · Manganese Acetate Tetrahydrate · Paraffin · Plantago Major · Sanguinaria Canadensis Root · Silicon Dioxide · Thyroid (Unspecified) · Valerian · Wood Creosote**

The TxGNN knowledge graph operates at the level of individual DrugBank-mapped entities. A multi-ingredient formulation of this kind — particularly one that lacks a DrugBank ID, has no INN as a unified entity, and includes both pharmacologically active botanicals and inert excipients (Paraffin, Silicon Dioxide, Ether) — cannot be reliably mapped to a single node in the knowledge graph. This is the most likely reason the model returned an empty prediction list.

Additionally, the mechanism of action is entirely unknown (`[Data Gap]`), and no original approved indication exists to anchor a mechanistic extrapolation. Without MOA data, it is not possible to reason from pharmacological class to a candidate new indication.

Several individual components do have known pharmacological profiles (e.g., Valerian as a mild sedative/anxiolytic, Crataegus as a cardiovascular herb, Sanguinaria Canadensis as a topical antimicrobial), but the interaction of all twelve components as a combined formulation has not been characterized.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on individual components:** Wood Creosote and Sanguinaria Canadensis Root both have known toxicity profiles at elevated doses. Thyroid (Unspecified) as an ingredient raises particular concern regarding thyroid hormone content and dosing. These risks cannot be formally assessed without full formulation details, concentration data, and a complete package insert.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned no predictions for this multi-ingredient formulation, and the absence of a DrugBank ID, approved indication, safety profile, and mechanism of action means there is no analytical foundation from which to evaluate repurposing potential. Proceeding without this baseline data would produce unreliable results.

**To proceed, the following is needed:**

- **Resolve drug identity**: Determine whether this formulation has a single authoritative INN, a brand name, or a registered homeopathic/herbal product code that can be used as a lookup key.
- **Obtain DrugBank ID**: Map at least the primary active ingredient(s) to DrugBank entries to enable TxGNN knowledge graph queries on individual components.
- **Characterize the active fraction**: Identify which of the twelve components are pharmacologically active vs. excipients, and obtain concentration/ratio data.
- **Retrieve safety data**: Download and parse the package insert (if available) to identify key warnings, contraindications, and drug interactions.
- **Re-run TxGNN per active component**: If a unified formulation-level prediction is not feasible, run individual predictions for the principal active ingredients (e.g., Valerian, Crataegus extract, Sanguinaria Canadensis) and synthesize results.
- **Address Data Gap DG001 (Safety)** and **DG002 (MOA)** before any further evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

